Matt Henriksen

For the listeners who are kind of new to that and, you know, thinking about, oh, it's just insulin delivery.

What is the second dual hormone and why is that important potentially for the patients?

Yeah, interesting.

Because then it sounds like from also from a business component, getting that insulin only pump out there allows you to now be able to generate the revenue and the potential cash flow to help finance that initial project that was going on.

Yeah.

And then, you know, just kind of closing out here, I mean, as playing your kind of CEO hat, you have a lot of different projects, you've got, you know, a lot of different, you know, and we've talked about, you know, not almost, we're almost at the state of getting to profitability for, you know, but for, you know, for a very new IPO company.

How do you make those decisions about, you know, accelerating growth or accelerating investments in one area or in one project versus, you know, being focused on that kind of, you know,

profitability trajectory and, you know, cash burn type of management.

Yeah.

Well, I look forward to following this story over the next few years.

Sean, thanks for joining us today.

Appreciate it.

And I'd like to thank our listeners for tuning in.

We hope you enjoy us for future episodes.

And if you want to stay up to date, please click the subscribe button on Spotify or your favorite streaming platform.

Take care.

Welcome to another exciting episode of the Vanguards of Healthcare series.

My name is Matt Henriksen, the medical technology analyst at Bloomberg Intelligence, which is the in-house equity research platform of Bloomberg LP.

We are pleased to have BioLink with us today, including CEO Rich Yang and co-founder, president, and CTO Jared Tangney.

BioLink is a privately held medical device company that is developing bio-wearables, including Shine, the first glucose sensor with no hypodermic needle for insertion.